Pathologic, Immunologic, and Clinical Analysis of the Microsatellite Instability Phenotype in Endometrial Carcinoma.

[1]  A. C. Marques,et al.  Improved NGS-based detection of microsatellite instability using tumor-only data , 2022, Frontiers in Oncology.

[2]  Marieke E. Ijsselsteijn,et al.  Discordant prognosis of mismatch repair deficiency in colorectal and endometrial cancer reflects variation in antitumour immune response and immune escape , 2022, The Journal of pathology.

[3]  A. Uguen,et al.  Idylla MSI test combined with immunohistochemistry is a valuable and cost effective strategy to search for microsatellite instable tumors of noncolorectal origin , 2022, Pathology international.

[4]  A. Tinker,et al.  Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study , 2022, Journal for ImmunoTherapy of Cancer.

[5]  G. Zannoni,et al.  New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines , 2021, Cancers.

[6]  T. Buhl,et al.  Managing Difficulties of Microsatellite Instability Testing in Endometrial Cancer-Limitations and Advantages of Four Different PCR-Based Approaches , 2021, Cancers.

[7]  K. Claes,et al.  Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer , 2021, Scientific Reports.

[8]  M. Kloor,et al.  Implications of Hereditary Origin on the Immune Phenotype of Mismatch Repair-Deficient Cancers: Systematic Literature Review , 2020, Journal of clinical medicine.

[9]  L. Insabato,et al.  Diagnostic Accuracy of Immunohistochemistry for Mismatch Repair Proteins as Surrogate of Microsatellite Instability Molecular Testing in Endometrial Cancer , 2020, Pathology & Oncology Research.

[10]  D. Evans,et al.  Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer , 2020, Frontiers in Immunology.

[11]  Hiroyuki Yamamoto,et al.  An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine. , 2019, Seminars in oncology.

[12]  M. Frey,et al.  Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population? , 2019, Cancer.

[13]  P. Keegan,et al.  FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors , 2019, Clinical Cancer Research.

[14]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[15]  Marc J. Williams,et al.  Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response , 2018, The Journal of pathology.

[16]  S. Kyo,et al.  Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer , 2017, Oncotarget.

[17]  N. Chaput,et al.  Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. , 2017, European journal of cancer.

[18]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[19]  S. Mok,et al.  Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters , 2017, Clinical Cancer Research.

[20]  H. Morreau,et al.  Practical guidance for mismatch repair-deficiency testing in endometrial cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  R. Eisenberg,et al.  Differences in Microsatellite Instability Profiles between Endometrioid and Colorectal Cancers: A Potential Cause for False-Negative Results? , 2017, The Journal of molecular diagnostics : JMD.

[22]  D. Tritchler,et al.  Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Lauren L. Ritterhouse,et al.  Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. , 2015, JAMA oncology.

[24]  F. Gao,et al.  Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Klenerman,et al.  POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer , 2015, Clinical Cancer Research.

[26]  H. Mackay,et al.  Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing , 2014, Cancer.

[27]  B. Melichar,et al.  Prognostic significance of CD3+ tumor-infiltrating lymphocytes in patients with endometrial carcinoma. , 2014, Anticancer research.

[28]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[29]  T. Smyrk,et al.  Tumor‐infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma , 2001, Cancer.